Share:
Transition Bio, Inc. a joint spin-out from the University of Cambridge and Havard University, has announced its $50 million Series A financing. A microfluidics-driven drug discovery platform company, Transition Bio uses biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates.
The investment round was led by Northpond Ventures and joined by Taiho Ventures, Bristol Myers Squibb and Magnetic Ventures. Cambridge Enterprise joined other existing seed investors in the Series A, among them Lifeforce Capital, the initial round’s lead investor.
Launched in 2020, Transition Bio brings together the unique fundamental knowledge and experience of Professor David Weitz, of Harvard University’s John A. Paulson School of Engineering and Applied Sciences, and Professor Tuomas Knowles, of the University of Cambridge’s Yusuf Hamied Department of Chemistry and the Cavendish Laboratory. Knowles serves as Transition Bio’s Chief Technology Officer. He and Weitz named the analysis of condensates cell biology based on the company’s proprietary technology CondensomicsTM.
The Series A capital will accelerate the progress made to date with the platform, which utilises microfluidics to drive high-throughput generation of proprietary data to enable machine learning-guided condensate target identification and drug discovery.
The company also announces that Shilpi Arora has joined as Senior Vice President of Discovery Research and Shaan C Gandhi has been appointed to the Board. In addition, Alfred W. Sandrock, Jr. has been appointed to the Board as an independent director. Co-founders Kelly Martin and Samuel Cohen, PhD, will continue to serve on the Board as Executive Chairman and Director, respectively.